Alamar Biosciences set an IPO price range of $15 to $17 per share, targeting expected net proceeds of about $133.2 million at the midpoint. The company planned to offer 9.375 million shares, with a 30-day option for underwriters to buy an additional 1.406 million shares. Alamar said the offering would support scale for its immunoassay panels and its Argo HT instrument, with assays spanning up to 220 targets across neurology, oncology, and immunology. The filing also references about $250 million raised across three venture rounds, plus an additional $50 million convertible notes financing in January. The IPO follows continued re-risking of lab-automation and diagnostic instrumentation platforms, where manufacturing and validation economics can drive sustained revenue after initial capital deployment. Investors will be watching post-IPO commercialization metrics, customer adoption rates, and performance benchmarking against existing assay platforms.